Overview

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized pilot phase I trial studies the side effects of dietary fat levels and abiraterone acetate uptake in patients with metastatic hormone-resistant prostate cancer. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Eating a low or high fat diet may increase the uptake of abiraterone acetate.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Abiraterone Acetate